<?xml version="1.0" encoding="UTF-8"?>
<feed xmlns="http://www.w3.org/2005/Atom" xmlns:dc="http://purl.org/dc/elements/1.1/">
  <title>STORRE Collection: Electronic copies of Faculty of Social Sciences letters (published in a journal).</title>
  <link rel="alternate" href="http://hdl.handle.net/1893/32510" />
  <subtitle>Electronic copies of Faculty of Social Sciences letters (published in a journal).</subtitle>
  <id>http://hdl.handle.net/1893/32510</id>
  <updated>2026-10-03T11:26:19Z</updated>
  <dc:date>2026-10-03T11:26:19Z</dc:date>
  <entry>
    <title>Benzodiazepines: the time for systematic change is now</title>
    <link rel="alternate" href="http://hdl.handle.net/1893/32515" />
    <author>
      <name>Robertson, Roy</name>
    </author>
    <author>
      <name>McAuley, Andrew</name>
    </author>
    <author>
      <name>Matheson, Catriona</name>
    </author>
    <id>http://hdl.handle.net/1893/32515</id>
    <updated>2021-07-14T00:01:18Z</updated>
    <published>2021-08-01T00:00:00Z</published>
    <summary type="text">Title: Benzodiazepines: the time for systematic change is now
Author(s): Robertson, Roy; McAuley, Andrew; Matheson, Catriona
Abstract: First paragraph: Schmitz has written an important and timely editorial which concerns itself with the risks of this widely used group of drugs and the, largely unsuccessful, strategies to reduce consumption. Prescribers and authors of guidelines from UK Royal Colleges and Government acknowledge the challenge of responding helpfully for a solution to anxiety, stress, sleeplessness and dependency and the risks of causing harm. One of the many paradoxes for prescribers is the subjective evidence of the benefits of these drugs set against the warnings, and sometimes threats, of supplying an inappropriate treatment.</summary>
    <dc:date>2021-08-01T00:00:00Z</dc:date>
  </entry>
</feed>

